Journey Medical (DERM) Cash from Investing Activities (2020 - 2023)

Journey Medical's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$5.0 million for Q1 2023.

• Quarterly Cash from Investing Activities rose 75.0% year-over-year to -$5.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was -$5.0 million (up 75.0% YoY) and the FY2024 annual result came in at -$15.0 million, down 200.0% from the prior year.
• Cash from Investing Activities was -$5.0 million for Q1 2023 at Journey Medical, up from -$20.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$200000.0 in Q4 2020 and bottomed at -$20.0 million in Q1 2022.
• A 4-year average of -$6.6 million and a median of -$3.1 million in 2021 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2021 — Cash from Investing Activities sank 500.0% — and 2023, when it jumped 75.0%.
• Journey Medical's Cash from Investing Activities stood at -$200000.0 in 2020, then sank by 500.0% to -$1.2 million in 2021, then tumbled by 1566.67% to -$20.0 million in 2022, then soared by 75.0% to -$5.0 million in 2023.
• Business Quant data shows DERM's Cash from Investing Activities at -$5.0 million in Q1 2023, -$20.0 million in Q1 2022, and -$1.2 million in Q4 2021.